Phase 2 N=140 Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)
Temporomandibular Joint Disorders
Primary: Average Pain — 4.7; 4.4; 4.5; 5.0 units on a scale — p=<.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
Recurrent Breast Carcinoma · Stage IV Breast Cancer
Primary: Level of EGFR Expression — 24; 8; 4; 0 participants
Phase 2 N=134 Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer
Head and Neck Cancer
Primary: Expression of p27 Cell Cycle Regulatory Protein at Baseline and Week 12 — 18.6; 15.1; 17.0; 14.5 percentage of cells
Phase 2 N=7 BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Melanoma
Primary: Number of Participants With Response According to RECIST v1.1 Criteria — 2; 2; 2; 1 Participants
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
Phase 2 N=1,063 Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
Infections, Meningococcal
Primary: Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule…
Phase 2 N=10 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Hypotension, Postural
Primary: Systolic Blood Pressure — 97; 103; 90; 88 mm Hg
Phase 2 N=35 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
Ovarian Clear Cell Adenocarcinoma · Recurrent Ovarian Carcinoma
Primary: Objective Tumor Response Rate (Complete and Partial Response) — 6.7 percentage of participants
Phase 2 N=63 Tailored Tobacco Quitline for Rural Veterans
Cigarette Smoking
Primary: Treatment Satisfaction — 17; 6; 16; 7 Participants
Phase 2 N=51 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
Dengue
Primary: Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine. — 3; 1; 11; 1 specified events
Phase 2 N=64 Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents
Pain · Nausea · Pruritus
Primary: Number of Participants With Naloxone Side Effects — 32 participants
Phase 2 N=23 Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
Asthma
Primary: Airway Reactivity — 5.08; 2.37 mg/ml
Phase 2 N=43 Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults
Infections, Streptococcal
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 0; 1; 0; 1 Participants
Phase 2 N=212 Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Primary: Progression Free Survival (PFS) — 4.3; 3.0; 4.2 Months — p=0.584